cancers-logo

Journal Browser

Journal Browser

Biomarkers for the Early Detection and Treatment of Cancers: 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 1539

Special Issue Editors


E-Mail Website
Guest Editor
Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland
Interests: biomarkers; non-invasive diagnosis; inflammation; tumor biomarkers; neuroinflammation; specific proteins; neurodegeneration
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269 Bialystok, Poland
Interests: biomarkers; non-invasive diagnosis; inflammation; tumor biomarkers; neuroinflammation; specific proteins
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The number of cancer cases increases every year. Prostate cancer is the most common cancer among men and breast cancer is the most common among women. However, a worrying phenomenon is the very large increase in the incidence of other types of cancer, including colorectal cancer and cancers of the urinary system. In developed countries, they are the second leading cause of death after cardiovascular diseases.

Rapidly developing cancer does not necessarily indicate that the patient's prognosis is poor. Many of these cancers can be successfully treated. However, there is a group of cancers that do not necessarily grow faster but are detected late, only after metastasis. Cancers that are detected early and properly treated do not have to be a judgement against which there is no appeal. Taking into account the above, this Special Issue aims to highlight new findings regarding biomarkers that could improve the early detection of cancer and assess their potential clinical application in rapid diagnosis during early stages of a developing disease. Tumor markers can be used in the early detection of cancer or during treatment to monitor its effectiveness and staging the cancer.

We are pleased to invite you to submit research and review articles related to the aim of this Special Issue.

Prof. Dr. Barbara Mroczko
Dr. Monika Gudowska-Sawczuk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • tumor biomarkers
  • tumor progression
  • early cancers
  • inflammatory mediators
  • early diagnosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

10 pages, 378 KiB  
Review
Diagnostic Utility of MicroRNAs in Pancreatic Cancers
by Wojciech Jelski, Jan Mroczko, Sylwia Okrasinska and Barbara Mroczko
Cancers 2024, 16(22), 3809; https://doi.org/10.3390/cancers16223809 - 12 Nov 2024
Cited by 1 | Viewed by 1158
Abstract
Pancreatic cancer (PC) is a serious malignant tumor with a high mortality rate, mainly due to late diagnosis and a lack of effective therapeutic interventions. The possibility of recognizing this cancer with reliable biomarkers using minimally invasive methods is of great importance for [...] Read more.
Pancreatic cancer (PC) is a serious malignant tumor with a high mortality rate, mainly due to late diagnosis and a lack of effective therapeutic interventions. The possibility of recognizing this cancer with reliable biomarkers using minimally invasive methods is of great importance for improving early detection, prognostic assessment, and targeted treatment methods. In recent years, small non-coding RNAs, especially microRNAs, have emerged as promising candidates for biomarkers of pancreatic cancer. Despite the methodological and analytical limitations of microRNA determination and a lack of available automated and standardized tests, a prospective systematic assessment of this new parameter’s use in the detection of pancreatic cancer is warranted. This review provides general information on the diagnostic and prognostic utility of microRNAs, which appear to be well-established in many studies. In summary, microRNAs are promising non-invasive biomarkers of pancreatic cancer, offering potential opportunities for early detection, prognosis, and treatment monitoring. As research in this field progresses, microRNAs should become valuable tools in the fight against pancreatic cancer. Full article
Show Figures

Figure 1

Back to TopTop